Rise in incidence of acute intermittent porphyria followed by conduction of various awareness campaigns in this regard is responsible for expansion of acute intermittent porphyria market size. Acute intermittent porphyria is a rare metabolic disorder that occurs due to deficiency of hydroxymethylbilane synthase (HMBS). The symptoms include nausea, abdominal pain, peripheral neuropathy, vomiting, and seizures.
The acute intermittent porphyria market manufacturers are working toward exploring the advantages offered by intravenous hematin apart from treating acute intermittent porphyria. They are propagating hematin as a source of imparting polyreactivity to human antibodies, which provide a better immune system.
Acute Intermittent Porphyria (AIP) is one of the rarest metabolic disorders characterized by partial deficiency of enzyme called porphobilinogen deaminase. The other factors contributing toward AIP include hormonal changes pertaining to puberty, use of certain recreational or prescribed drugs that may be allergic, excessive consumption of alcohol, and dietary or fasting changes.
As of now, treatment of AIP means preventing attacks of AIP by educating the patients to avert potential triggers. Some of these attacks in the form of peripheral neuropathy, seizures, and higher blood pressure can be treated through intravenous hematin.
Porphyrias are usually classified into erythropoietic and hepatic types. In the former ones, porphyrin precursors and porphyrins are excessively formed in bone marrow, where as they are formed in the liver in the second one. The term ‘acute’ is used here to denote the sudden pain caused to the lower urinary tract.
| Attribute | Detail |
|---|---|
| Market Drivers |
|
Symptoms of lower urinary tract (LUT) dysfunction include urinary incontinence, unwanted urinary retention, and recurrent urinary tract infections. Though age-related LUT dysfunction is common, the National Institutes of Health states that LUT symptoms are affecting over 2.3 billion individuals worldwide.
Research says that LUT dysfunction is related to faulty metabolism. The National Institute of Health affirms that metabolic disorders can result in increase in thirst and urination, especially during the night.
LUT dysfunction, if not treated on time, may develop into acute intermittent porphyria. Acute Intermittent Porphyria (AIP) is an extension of the metabolic syndrome mentioned above. In other words, it is triggered by urinary retention, myalgia, sleeplessness, and aberrant urine color, apart from being a congenital disease.
Need to control lower urinary tract infections to avert their culmination into AIP is thus boosting the acute intermittent porphyria market revenue.
The common symptoms of acute intermittent porphyria include chronic blistering lesions on sun-exposed areas, abdominal pain, or hyponatremia in young women, and burning and itching pain on sun-exposed skin.
However, the symptoms mentioned above are not taken seriously by majority of the ones having them. They are seen waiting for the body’s healing power to take its course or asking the chemist about general medications. The American Porphyria Foundation, in line with creating awareness in this regard, organizes a ‘Porphyria Awareness Week’ every year in the month of April. #LETSTALKPORPHYRIA is the campaign emphasizing conversation regarding porphyria. The community members are encouraged to educate as well as partake in dialogues with peers as well as healthcare professionals relating to treatment of this disease.
Conduction of such awareness campaigns regarding acute intermittent porphyria is thus riving the global acute intermittent porphyria market.
| Attribute | Detail |
|---|---|
| Leading Region | North America |
As per the latest acute intermittent porphyria market analysis, North America held the largest share in metabolic porphyria landscape in 2023 and the dominance is expected to continue during the forecast period. This is attributed to increase in the number of individuals contracting metabolic abnormalities.
The acute intermittent porphyria market growth in Asia Pacific is owing to rise in demand for innovative approaches of treatment of acute intermittent porphyria. South Korea, China, and India are at the forefront in hepatic porphyria therapeutics in this region.
The companies operating in the acute intermittent porphyria industry are working toward devising new therapeutics to combat the disease.
Alnylam Pharmaceuticals, Inc., Clinuvel Pharmaceuticals Ltd., BioMarin Pharmaceutical Inc., Recordati, Quest Diagnostics, Invitae Corp., Laboratory Corporation of America Holdings (Labcorp), and ARUP Laboratories are some of the key players covered in the acute intermittent porphyria market report.
These companies have been highlighted based on parameters such as company overview, business strategies, financial overview, product portfolio, and business segments.
| Attribute | Detail |
|---|---|
| Market Size in 2023 | US$ 4.6 Mn |
| Market Forecast (Value) in 2034 | US$ 7.1 Mn |
| Growth Rate (CAGR) | 3.9% |
| Forecast Period | 2024-2034 |
| Historical Data Available for | 2020-2022 |
| Quantitative Units | US$ Mn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available Upon Request |
| Pricing | Available Upon Request |
It was valued at US$ 4.6 Mn in 2023
It is projected to grow at a CAGR of 3.9% from 2024 to 2034
Growing prevalence of metabolic diseases and lower urinary tract infections and rise in awareness about acute intermittent porphyria
Hospitals segment accounted for the largest share in 2023
North America was the dominant region in 2023
Alnylam Pharmaceuticals, Inc., Clinuvel Pharmaceuticals Ltd., BioMarin Pharmaceutical Inc., Recordati, Quest Diagnostics, Invitae Corp., Laboratory Corporation of America Holdings (Labcorp), and ARUP Laboratories
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Acute Intermittent Porphyria Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Acute Intermittent Porphyria Market Analysis and Forecast, 2020-2034
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product /Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Acute Intermittent Porphyria Market Analysis and Forecast, by Diagnosis
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Diagnosis, 2020-2034
6.3.1. Blood Test
6.3.2. Urine Test
6.3.3. DNA Test
6.3.4. Serum Test
6.4. Market Attractiveness Analysis, by Diagnosis
7. Global Acute Intermittent Porphyria Market Analysis and Forecast, by Treatment
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Treatment, 2020-2034
7.3.1. Gonadotropin-Releasing Hormone Analogues
7.3.2. Prophylactic Hematin Infusions
7.4. Market Attractiveness Analysis, by Treatment
8. Global Acute Intermittent Porphyria Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by End-user, 2020-2034
8.3.1. Hospitals
8.3.2. Clinics
8.3.3. Research Centers
8.4. Market Attractiveness Analysis, by End-user
9. Global Acute Intermittent Porphyria Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2020-2034
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Acute Intermittent Porphyria Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Diagnosis, 2020-2034
10.3.1. Blood Test
10.3.2. Urine Test
10.3.3. DNA Test
10.3.4. Serum Test
10.4. Market Value Forecast, by Treatment, 2020-2034
10.4.1. Gonadotropin-Releasing Hormone Analogues
10.4.2. Prophylactic Hematin Infusions
10.5. Market Value Forecast, by End-user, 2020-2034
10.5.1. Hospitals
10.5.2. Clinics
10.5.3. Research Centers
10.6. Market Value Forecast, by Country, 2020-2034
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Diagnosis
10.7.2. By Treatment
10.7.3. By End-user
10.7.4. By Country
11. Europe Acute Intermittent Porphyria Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Diagnosis, 2020-2034
11.3.1. Blood Test
11.3.2. Urine Test
11.3.3. DNA Test
11.3.4. Serum Test
11.4. Market Value Forecast, by Treatment, 2020-2034
11.4.1. Gonadotropin-Releasing Hormone Analogues
11.4.2. Prophylactic Hematin Infusions
11.5. Market Value Forecast, by End-user, 2020-2034
11.5.1. Hospitals
11.5.2. Clinics
11.5.3. Research Centers
11.6. Market Value Forecast, by Country/Sub-region, 2020-2034
11.6.1. Germany
11.6.2. U.K.
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Diagnosis
11.7.2. By Treatment
11.7.3. By End-user
11.7.4. By Country/Sub-region
12. Asia Pacific Acute Intermittent Porphyria Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Diagnosis, 2020-2034
12.3.1. Blood Test
12.3.2. Urine Test
12.3.3. DNA Test
12.3.4. Serum Test
12.4. Market Value Forecast, by Treatment, 2020-2034
12.4.1. Gonadotropin-Releasing Hormone Analogues
12.4.2. Prophylactic Hematin Infusions
12.5. Market Value Forecast, by End-user, 2020-2034
12.5.1. Hospitals
12.5.2. Clinics
12.5.3. Research Centers
12.6. Market Value Forecast, by Country/Sub-region, 2020-2034
12.6.1. China
12.6.2. Japan
12.6.3. India
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1. By Diagnosis
12.7.2. By Treatment
12.7.3. By End-user
12.7.4. By Country/Sub-region
13. Latin America Acute Intermittent Porphyria Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Diagnosis, 2020-2034
13.3.1. Blood Test
13.3.2. Urine Test
13.3.3. DNA Test
13.3.4. Serum Test
13.4. Market Value Forecast, by Treatment, 2020-2034
13.4.1. Gonadotropin-Releasing Hormone Analogues
13.4.2. Prophylactic Hematin Infusions
13.5. Market Value Forecast, by End-user, 2020-2034
13.5.1. Hospitals
13.5.2. Clinics
13.5.3. Research Centers
13.6. Market Value Forecast, by Country/Sub-region, 2020-2034
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
13.7.1. By Diagnosis
13.7.2. By Treatment
13.7.3. By End-user
13.7.4. By Country/Sub-region
14. Middle East & Africa Acute Intermittent Porphyria Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Diagnosis, 2020-2034
14.3.1. Blood Test
14.3.2. Urine Test
14.3.3. DNA Test
14.3.4. Serum Test
14.4. Market Value Forecast, by Treatment, 2020-2034
14.4.1. Gonadotropin-Releasing Hormone Analogues
14.4.2. Prophylactic Hematin Infusions
14.5. Market Value Forecast, by End-user, 2020-2034
14.5.1. Hospitals
14.5.2. Clinics
14.5.3. Research Centers
14.6. Market Value Forecast, by Country/Sub-region, 2020-2034
14.6.1. GCC Countries
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
14.7.1. By Diagnosis
14.7.2. By Treatment
14.7.3. By End-user
14.7.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2023)
15.3. Company Profiles
15.3.1. Alnylam Pharmaceuticals, Inc.
15.3.1.1. Company Overview
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. Clinuvel Pharmaceuticals Ltd.
15.3.2.1. Company Overview
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. BioMarin Pharmaceutical Inc.
15.3.3.1. Company Overview
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. Recordati
15.3.4.1. Company Overview
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. Quest Diagnostics
15.3.5.1. Company Overview
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. Invitae Corp.
15.3.6.1. Company Overview
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. Laboratory Corporation of America Holdings (Labcorp)
15.3.7.1. Company Overview
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. ARUP Laboratories
15.3.8.1. Company Overview
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
List of Tables
Table 01: Global Acute Intermittent Porphyria Market Size (US$ Mn) Forecast, by Diagnosis, 2020-2034
Table 02: Global Acute Intermittent Porphyria Market Size (US$ Mn) Forecast, by Treatment, 2020-2034
Table 03: Global Acute Intermittent Porphyria Market Size (US$ Mn) Forecast, by End-user, 2020-2034
Table 04: Global Acute Intermittent Porphyria Market Size (US$ Mn) Forecast, by Region, 2020-2034
Table 05: North America Acute Intermittent Porphyria Market Size (US$ Mn) Forecast, by Country, 2020-2034
Table 06: North America Acute Intermittent Porphyria Market Size (US$ Mn) Forecast, by Diagnosis, 2020-2034
Table 07: North America Acute Intermittent Porphyria Market Size (US$ Mn) Forecast, by Treatment, 2020-2034
Table 08: North America Acute Intermittent Porphyria Market Size (US$ Mn) Forecast, by End-user, 2020-2034
Table 09: Europe Acute Intermittent Porphyria Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
Table 10: Europe Acute Intermittent Porphyria Market Size (US$ Mn) Forecast, by Diagnosis, 2020-2034
Table 11: Europe Acute Intermittent Porphyria Market Size (US$ Mn) Forecast, by Treatment, 2020-2034
Table 12: Europe Acute Intermittent Porphyria Market Size (US$ Mn) Forecast, by End-user, 2020-2034
Table 13: Asia Pacific Acute Intermittent Porphyria Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
Table 14: Asia Pacific Acute Intermittent Porphyria Market Size (US$ Mn) Forecast, by Diagnosis, 2020-2034
Table 15: Asia Pacific Acute Intermittent Porphyria Market Size (US$ Mn) Forecast, by Treatment, 2020-2034
Table 16: Asia Pacific Acute Intermittent Porphyria Market Size (US$ Mn) Forecast, by End-user, 2020-2034
Table 17: Latin America Acute Intermittent Porphyria Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
Table 18: Latin America Acute Intermittent Porphyria Market Size (US$ Mn) Forecast, by Diagnosis, 2020-2034
Table 19: Latin America Acute Intermittent Porphyria Market Size (US$ Mn) Forecast, by Treatment, 2020-2034
Table 20: Latin America Acute Intermittent Porphyria Market Size (US$ Mn) Forecast, by End-user, 2020-2034
Table 21: Middle East & Africa Acute Intermittent Porphyria Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
Table 22: Middle East & Africa Acute Intermittent Porphyria Market Size (US$ Mn) Forecast, by Diagnosis, 2020-2034
Table 23: Middle East & Africa Acute Intermittent Porphyria Market Size (US$ Mn) Forecast, by Treatment, 2020-2034
Table 24: Middle East & Africa Acute Intermittent Porphyria Market Size (US$ Mn) Forecast, by End-user, 2020-2034
List of Figures
Figure 01: Global Acute Intermittent Porphyria Market Size (US$ Mn) and Distribution (%), by Region, 2023 and 2034
Figure 02: Global Acute Intermittent Porphyria Market Revenue (US$ Mn), by Diagnosis, 2023
Figure 03: Global Acute Intermittent Porphyria Market Value Share, by Diagnosis, 2023
Figure 04: Global Acute Intermittent Porphyria Market Revenue (US$ Mn), by Treatment, 2023
Figure 05: Global Acute Intermittent Porphyria Market Value Share, by Treatment, 2023
Figure 06: Global Acute Intermittent Porphyria Market Revenue (US$ Mn), by End-user, 2023
Figure 07: Global Acute Intermittent Porphyria Market Value Share, by End-user, 2023
Figure 08: Global Acute Intermittent Porphyria Market Value Share, by Region, 2023
Figure 09: Global Acute Intermittent Porphyria Market Value (US$ Mn) Forecast, 2020-2034
Figure 10: Global Acute Intermittent Porphyria Market Value Share Analysis, by Diagnosis, 2023 and 2034
Figure 11: Global Acute Intermittent Porphyria Market Attractiveness Analysis, by Region, 2024-2034
Figure 12: Global Acute Intermittent Porphyria Market Value Share Analysis, by Treatment, 2023 and 2034
Figure 13: Global Acute Intermittent Porphyria Market Attractiveness Analysis, by Treatment, 2024-2034
Figure 14: Acute Intermittent Porphyria Market Value Share Analysis, by End-user, 2023 and 2034
Figure 15: Global Acute Intermittent Porphyria Market Attractiveness Analysis, by End-user, 2024-2034
Figure 16: Global Acute Intermittent Porphyria Market Value Share Analysis, by Region, 2023 and 2034
Figure 17: Global Acute Intermittent Porphyria Market Attractiveness Analysis, by Region, 2024-2034
Figure 18: North America Acute Intermittent Porphyria Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 19: North America Acute Intermittent Porphyria Market Attractiveness Analysis, by Country, 2024-2034
Figure 20: North America Acute Intermittent Porphyria Market Value Share Analysis, by Country, 2023 and 2034
Figure 21: North America Acute Intermittent Porphyria Market Value Share Analysis, by Diagnosis, 2023 and 2034
Figure 22: North America Acute Intermittent Porphyria Market Value Share Analysis, by Treatment, 2023 and 2034
Figure 23: North America Acute Intermittent Porphyria Market Value Share Analysis, by End-user, 2023 and 2034
Figure 24: North America Acute Intermittent Porphyria Market Attractiveness Analysis, by Region, 2024-2034
Figure 25: North America Acute Intermittent Porphyria Market Attractiveness Analysis, by Treatment, 2024-2034
Figure 26:North America Acute Intermittent Porphyria Market Attractiveness Analysis, by End-user, 2024-2034
Figure 27: Europe Acute Intermittent Porphyria Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 28: Europe Acute Intermittent Porphyria Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 29: Europe Acute Intermittent Porphyria Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 30: Europe Acute Intermittent Porphyria Market Value Share Analysis, by Diagnosis, 2023 and 2034
Figure 31: Europe Acute Intermittent Porphyria Market Value Share Analysis, by Treatment, 2023 and 2034
Figure 32: Europe Acute Intermittent Porphyria Market Value Share Analysis, by End-user, 2023 and 2034
Figure 33: Europe Acute Intermittent Porphyria Market Attractiveness Analysis, by Region, 2024-2034
Figure 34: Europe Acute Intermittent Porphyria Market Attractiveness Analysis, by Treatment, 2024-2034
Figure 35: Europe Acute Intermittent Porphyria Market Attractiveness Analysis, by End-user, 2024-2034
Figure 36: Asia Pacific Acute Intermittent Porphyria Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 37: Asia Pacific Acute Intermittent Porphyria Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 38: Asia Pacific Acute Intermittent Porphyria Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 39: Asia Pacific Acute Intermittent Porphyria Market Value Share Analysis, by Diagnosis, 2023 and 2034
Figure 40: Asia Pacific Acute Intermittent Porphyria Market Value Share Analysis, by Treatment, 2023 and 2034
Figure 41: Asia Pacific Acute Intermittent Porphyria Market Value Share Analysis, by End-user, 2023 and 2034
Figure 42: Asia Pacific Acute Intermittent Porphyria Market Attractiveness Analysis, by Region, 2024-2034
Figure 43: Asia Pacific Acute Intermittent Porphyria Market Attractiveness Analysis, by Treatment, 2024-2034
Figure 44: Asia Pacific Acute Intermittent Porphyria Market Attractiveness Analysis, by End-user, 2024-2034
Figure 45: Latin America Acute Intermittent Porphyria Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 46: Latin America Acute Intermittent Porphyria Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 47: Latin America Acute Intermittent Porphyria Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 48: Latin America Acute Intermittent Porphyria Market Value Share Analysis, by Diagnosis, 2023 and 2034
Figure 49: Latin America Acute Intermittent Porphyria Market Value Share Analysis, by Treatment, 2023 and 2034
Figure 50: Latin America Acute Intermittent Porphyria Market Value Share Analysis, by End-user, 2023 and 2034
Figure 51: Latin America Acute Intermittent Porphyria Market Attractiveness Analysis, by Region, 2024-2034
Figure 52: Latin America Acute Intermittent Porphyria Market Attractiveness Analysis, by Treatment, 2024-2034
Figure 53: Latin America Acute Intermittent Porphyria Market Attractiveness Analysis, by End-user, 2024-2034
Figure 54: Middle East & Africa Acute Intermittent Porphyria Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 55: Middle East & Africa Acute Intermittent Porphyria Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 56: Middle East & Africa Acute Intermittent Porphyria Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 57: Middle East & Africa Acute Intermittent Porphyria Market Value Share Analysis, by Diagnosis, 2023 and 2034
Figure 58: Middle East & Africa Acute Intermittent Porphyria Market Value Share Analysis, by Treatment, 2023 and 2034
Figure 59: Middle East & Africa Acute Intermittent Porphyria Market Value Share Analysis, by End-user, 2023 and 2034
Figure 60: Middle East & Africa Acute Intermittent Porphyria Market Attractiveness Analysis, by Region, 2024-2034
Figure 61: Middle East & Africa Acute Intermittent Porphyria Market Attractiveness Analysis, by Treatment, 2024-2034
Figure 62: Middle East & Africa Acute Intermittent Porphyria Market Attractiveness Analysis, by End-user, 2024-2034
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Acute Intermittent Porphyria Market
